Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1

Status

Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 7OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 1Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × brexucabtagene autoleucel × 1 year × Clear all
NCT05495464 2026-05-20

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT06144606 2026-03-31

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06553872 2026-03-31

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
60 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
150 enrolled 23 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06213311 2026-01-14

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡